Intelligence · Patents
Patents expiring in 2037
Annual patent cliff calendar for 2037 — US pharmaceutical patents by expiration date.
- Patents
- 1,615
Quick answer
1,615 indexed pharmaceutical patents have expiration dates in 2037. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 9566329
Live, attenuated rubella vector to express vaccine antigens
granted -
US 9566314
Extracellular vesicles comprising recombinant lysosomal transmembrane protein
granted -
US 9566294
Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
granted -
US 9566283
Compositions and methods for inhibition of the JAK pathway
granted -
US 9566271
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
granted -
US 9566278
Protein kinase C inhibitors and uses thereof
granted -
US 9566251
Volatile anesthetic compositions and methods of use
granted -
US 9566232
Compositions and methods for enhancing the efficacy of contraceptive microbicides
granted -
US 9565857
Antimicrobial solutions
granted -
US 9567402
Internalizing human monoclonal antibodies targeting prostate and other cancer cells
granted -
US 9566348
Methods and compositions for the treatment of cancer and infectious disease using alpha(2) macroglobulin-antigenic molecule complexes
granted -
US 9567566
HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants
granted -
US 9565840
Fibrotic non-human animal, and use thereof
granted -
US 9567592
Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
granted -
US 9566250
Artificial tissue constructs comprising alveolar cells and methods for using the same
granted -
US 9566295
GNAQ targeted dsRNA compositions and methods for inhibiting expression
granted -
US 9566310
Methods of treating muscular dystrophy
granted -
US 9567345
Pharmaceutically active pyrazolo-triazine derivatives
granted -
US 9572802
Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity
granted -
US 9572809
Combination therapy to treat Mycobacterium diseases
granted -
US 9573908
Broad spectrum pro-quorum-sensing molecules as inhibitors of virulence in vibrios
granted -
US 9573906
Therapeutic compounds
granted -
US 9573948
Triazolopyridine compounds and methods for the treatment of cystic fibrosis
granted -
US 9574004
Methods for treating or preventing asthma by administering an IL-4R antagonist
granted -
US 9574243
Compositions and methods for the treatment of influenza infection
granted -
US 9574193
Methods and compositions for modulating apolipoprotein (a) expression
granted -
US 9574192
Serapina1 iRNA compositions and methods of use thereof
granted -
US 9574211
Methods and compositions for prevention or treatment of a disease
granted -
US 9574012
AGR2 blocking antibody and use thereof
granted -
US 9573977
Method for preventing neoplastic transformation by inhibition of retinoblastoma protein inactivation
granted -
US 9574191
Selective inhibition of polyglutamine protein expression
granted -
US 9572883
Oncolytic rhabdovirus
granted -
US 9573953
Heteroaromatic compounds as PI3 kinase modulators and methods of use
granted -
US 9573922
Process-scale synthesis of urolithins
granted -
US 9572910
pH responsive self-healing hydrogels formed by boronate-catechol complexation
granted -
US 9573903
Heterocyclic compound
granted -
US 9572898
Functionalized fluorine containing phthalocyanine molecules
granted -
US 9572862
Methods for promoting lipolysis and oxidation in liver and adipose tissue using catestatin
granted -
US 9572828
Treatment for melanoma
granted -
US 9572881
Halogenated compounds for photodynamic therapy
granted -
US 9572873
Method of inducing a T lymphocyte response using T-cell immunogens derived from anti-viral proteins
granted -
US 9572870
Delivery of therapeutic compounds to the brain and other tissues
granted -
US 9580472
Anti-microbial peptides and methods of use thereof
granted -
US 9580718
Attenuated live bacteria with increased acid resistance and methods of use thereof
granted -
US 9580711
Lipid particles with asymmetric cationic lipids for RNA delivery
granted -
US 9580690
Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
granted -
US 9580492
Monoclonal antibodies that neutralize anthrax toxins
granted -
US 9579406
Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
granted
Frequently asked questions
How many pharma patents expire in 2037?
1,615 published patents in our USPTO index have expiration dates falling in calendar year 2037.